- Super Micro Computer (SMCI) +20% on better-than-expected Q4 prelim results.
- ToughBuilt Industries (TBLT) +16%.
- MoonLake Immunotherapeutics (MLTX) +14%.
- Visionary Education Technology Holdings (VEDU) +12%.
- Olema Pharmaceuticals (OLMA) +11% as FDA grants fast track status to OP-1250 for breast cancer subtype.
- aTyr Pharma (LIFE) +11%.
- Tabula Rasa HealthCare (TRHC) +11% on raised Q2 revenue guidance.
- Blue Apron Holdings (APRN) +7% after Benchmark turns bullish.
- Nokia Oyj (NOK) +7% on Q2 results.
- XTL Biopharmaceuticals (XTLB) +7%.
- Karyopharm Therapeutics (KPTI) +6% wins full EU approval for multiple myeloma therapy.